Achaogen develops drugs to treat infectious disease and address the problem of drug resistance.
Congratulations to OPTM on FDA approval for Dificid! We need more new antibiotics.
Great article on companies addressing C. diff and MRSA–The pipeline is stocked for MRSA but empty for Gram-negatives. http://bloom.bg/keNHtx
We’ll be tweeting thoughts about our company, antibiotic R&D, bacterial resistance, and more. Spread the word and send us your feedback!
Hello world from Achaogen –